谷氨酰胺的选择性吸收胃肠道:确认在人类研究中。

文章的细节

引用

复制到剪贴板

McAnena橙汁,摩尔FA,摩尔EE,琼斯TN,帕森斯P

谷氨酰胺的选择性吸收胃肠道:确认在人类研究中。

Br J Surg. 1991年4月,78 (4):480 - 2。

PubMed ID

1903318 (在PubMed

]

文摘

最近的动物数据表明,肠道中起着更重要的代谢作用。在至关重要的疾病,肠道屏障功能的中断可能会导致慢性hypermetabolic状态和导致multiorgan失败。动物研究表明肠上皮细胞的胃肠道使用谷氨酰胺作为呼吸期间燃料和重要疾病的消费由肠道显著增加谷氨酰胺。谷氨酰胺的选择性吸收肠道,迄今为止,人类还没有得到证实。7持续多系统创伤需要剖腹手术的患者进行了门户静脉导管。这样做是通过仔细重新开放了脐静脉和便利地获取门静脉左支的中央静脉导管使用标准。门户静脉和全身血液样本记录操作后5天。氨基酸含量的发行量都记录在48 h和5天。使用学生的t测试相关样本,个体之间的差异氨基酸在门户和系统性发行量比较。在48 h,意思是(他)门户静脉谷氨酰胺是系统性的每分85(5)的水平(253年与296年相比(80)(90)mumol /毫升,P小于0.002)。 At 5 days, portal glutamine was 87(3) per cent of the systemic levels (255(69) compared with 292(83) mumol/ml, P less than 0.003). Levels of citrulline, a breakdown product of glutamine metabolism, were elevated in the portal venous circulation at 48 h (20(4) compared with 16(3) mumol/ml, P less than 0.005) and at 5 days (21(5) compared with 14(3) mumol/ml, P less than 0.002). No significant differences between any of the other amino acids analysed were identified. This study confirms, for the first time in humans, that selective uptake of glutamine occurs in the gut. In stressed states, glutamine deficiency is associated with gut mucosal atrophy. This has significant implications as glutamine is not provided in most commercially available parenteral and enteral nutrition formulations.

DrugBank数据引用了这篇文章

药物

谷酰胺